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Abstract
Background: Automatic identification of notifiable diseases from electronic medical records can potentially improve the
timeliness and completeness of public health surveillance. We describe the development and implementation of an
algorithm for prospective surveillance of patients with acute hepatitis B using electronic medical record data.
Methods: Initial algorithms were created by adapting Centers for Disease Control and Prevention diagnostic criteria for
acute hepatitis B into electronic terms. The algorithms were tested by applying them to ambulatory electronic medical
record data spanning 1990 to May 2006. A physician reviewer classified each case identified as acute or chronic infection.
Additional criteria were added to algorithms in serial fashion to improve accuracy. The best algorithm was validated by
applying it to prospective electronic medical record data from June 2006 through April 2008. Completeness of case capture
was assessed by comparison with state health department records.
Findings: A final algorithm including a positive hepatitis B specific test, elevated transaminases and bilirubin, absence of
prior positive hepatitis B tests, and absence of an ICD9 code for chronic hepatitis B identified 112/113 patients with acute
hepatitis B (sensitivity 97.4%, 95% confidence interval 94–100%; specificity 93.8%, 95% confidence interval 87–100%).
Application of this algorithm to prospective electronic medical record data identified 8 cases without false positives. These
included 4 patients that had not been reported to the health department. There were no known cases of acute hepatitis B
missed by the algorithm.
Conclusions: An algorithm using codified electronic medical record data can reliably detect acute hepatitis B. The
completeness of public health surveillance may be improved by automatically identifying notifiable diseases from electronic
medical record data.
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Introduction
Public health surveillance for notifiable diseases has traditionally
relied upon clinicians to spontaneously report new diagnoses of
relevant conditions. Clinician-initiated reporting, however, is often
incomplete and delayed.[1,2] Electronic laboratory reporting
systems have improved both the volume and timeliness of
reporting [3,4,5,6] but these systems have important limitations:
they cannot report purely clinical diagnoses (such as culture-
negative tuberculosis), indicate when a result is likely a false
positive (such as positive hepatitis A IgM in an asymptomatic
patient getting screening tests), nor render diagnoses that require
integration of laboratory tests along with patient clinical data and
prior test results (such as acute hepatitis B). The lack of specificity
in electronic laboratory reporting increases workload for health
departments compelled to investigate suggestive but non-specific
lab results.[7] In addition, electronic laboratory reporting systems
do not report clinical data that can be crucial to guiding public
health interventions such as patients’ pregnancy status, prescribed
treatments, and full contact information.
Electronic medical record systems are a promising new strategy
to improve public health surveillance.[8] These systems encode a
wide array of clinical data including patient demographics, current
and prior diagnoses, medication prescriptions, and laboratory
results. These data might potentially be used to detect notifiable
diseases that cannot be found by electronic laboratory reporting
systems as well as to convey important information to public
health authorities on patient demographics, clinical status, and
prescribed treatments. Accurate identification of complex diagno-
ses from electronic medical records, however, requires the
development of novel detection algorithms since diagnostic codes
alone, such as International Classification of Diseases Ninth
Revision codes (ICD9), are imprecise.[9,10]
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complex notifiable diseases using electronic medical record data,
we sought to develop an algorithm to identify cases of acute
hepatitis B using electronic medical record data. Acute hepatitis B
was chosen as a ‘‘proof of principle’’ condition because it is a
complex diagnosis of public health importance that is largely
transparent to electronic laboratory reporting systems.
Accurate identification of acute hepatitis B is essential to public
health practice. Public health practitioners seek acute cases to gauge
the changing epidemiology of hepatitis B and the impact of universal
vaccination programs.[11] Acute cases also trigger high-priority
interventions to limit the spread of disease. Clinician-initiated
reporting of acute hepatitis B, however, is typically incomplete,
delayed, and inaccurate: public health departments have found that
upto40%ofcasesreportedbycliniciansasacutehepatitisBturnout
to be chronic infection upon further investigation.[12] Electronic
laboratory reporting systems have improved both the volume and
timeliness of hepatitis B case reports but these systems typically only
report the presence of a positive test for hepatitis B–they cannot
distinguish between acute and chronic infections.[6]
The central challenge for both clinicians and lab surveillance
systems in identifying acute hepatitis B is distinguishing acute cases
from ‘‘flares’’ of previously undiagnosed chronic disease.[11,12]
Both can present with markedly elevated transaminases and
positive hepatitis B specific tests such as hepatitis B surface antigen,
envelope antigen, and viral DNA. Clinicians can make a probable
distinction between acute and chronic disease by considering the
context of diagnosis–asymptomatic patients diagnosed after
incidental discovery of elevated transaminases most likely have
chronic disease whereas newly symptomatic patients with elevated
transaminases likely have acute disease. This distinction is not
entirely reliable, however, since new infections, hepatotoxins,
cholelithiasis, and other unidentified factors can cause dramatic
‘‘flares’’ of chronic hepatitis B that resemble acute infection.
Laboratory systems can only identify acute cases amongst patients
that have positive tests for IgM to hepatitis B core antigen but this
test is rarely ordered by clinicians investigating hepatitis.[13]
Analysis of data captured in electronic medical record systems and
regional healthinformation exchanges mightbe ableto overcome the
limitations of both clinician-initiated and electronic laboratory
reporting of acute hepatitis B. Integration of multiple streams of
electronic health data present in these systems such as current and
prior diagnoses, prescriptions, and laboratory results may yield
enough information to distinguish acute infection from chronic
disease. We consequently sought to create and validate an algorithm
to distinguish acute from chronic hepatitis B using codified electronic
medical record data to facilitate automated public health surveillance.
Methods
The clinical surveillance definition for acute hepatitis B published
by the Centers for Disease Control and Prevention (CDC), shown in
Table 1, was adapted to create two pilot electronic algorithms: 1)
serum transaminases .5 times normal and positive IgM to hepatitis
B core antigen, and 2) serum transaminases .5 times normal and a
positive hepatitis B specific test (surface antigen, antibody to core
antigen, or DNA).[11] The algorithms were refined by excluding all
patients with prior positive laboratory tests for hepatitis B or an
ICD9 code for chronic hepatitis B. We then tested the algorithms by
applying them to comprehensive electronic medical record data
from Harvard Vanguard Medical Associates from January 1990
through May 2006. Harvard Vanguard Medical Associates is a
large, multispecialty, ambulatory medical practice based in Eastern
Massachusetts with approximately 350,000 patients. The chart of
each patient identified by the algorithms was reviewed by an
infectious disease specialist to establish a diagnosis of acute versus
chronic disease using the CDC definition as a reference standard.
AcutehepatitisBwasdefinedasthepresenceofapositivehepatitis
B specific test (surface antigen or envelope antigen or DNA or
antibody to hepatitis B core antigen) and one or both of the
following: 1) an acute presentation of symptomatic disease consistent
with hepatitis B (fever, nausea, vomiting, abdominal pain, fatigue,
myalgias, jaundice, dark urine, and/or pale stool); and 2) prior or
subsequent negative surface antigenemia without intervening
hepatitis B therapy. Chronic hepatitis B was defined as a positive
hepatitis B specific test in a patient who was asymptomatic or had a
known history of hepatitis B by patient report or prior positive
hepatitis B specifictests.Candidatealgorithmswererefined basedon
manual analysis of false positive cases identified by the algorithm.
The final algorithm was validated by applying it to an
independent dataset of electronic medical record data gathered
from Atrius Health between June 2006 and April 2008. Atrius
Health is the product of a merger between Harvard Vanguard
Medical Associates and four other ambulatory medical practices in
Eastern Massachusetts. The combined practice serves over
600,000 patients at 35 clinical sites. The algorithm was applied
to the Atrius Health dataset within the test environment of a novel
electronic system designed to prospectively scan electronic medical
record data to automatically identify and report notifiable diseases
on a daily basis.[8,14] We assessed completeness of case capture in
the validation dataset by comparing its incidence-density of acute
hepatitis B with the annual incidence density in the three most
recent years of the derivation set. Recent annual incidence-
densities were chosen over incidence-density of the full dataset
because the incidence of hepatitis B has been dropping
dramatically since universal vaccination was introduced in
1991.[11] We also validated the final algorithm against an
external standard by searching state health department records
for all cases of acute hepatitis B diagnosed between June 2006 and
April 2008 to determine whether any cases independently reported
by Atrius clinicians or laboratories were missed by the algorithm.
For comparison sake, we also estimated the positive predictive
value of identifying acute hepatitis B purely from the presence of
an ICD9 code for acute hepatitis B (070.30). We did so by
selecting 50 patients at random from amongst all who were given
this code within the past two years.
All candidate algorithms are presented in Table 2.
Results
Analysis of electronic medical record data spanning 1990
through May 2006 yielded 11 patients with transaminases .5
times normal and positive IgM to hepatitis B core antigen. A
Table 1. Centers for Disease Control and Prevention
surveillance definition for acute hepatitis B.
Clinical Criteria An acute illness with:
a) discrete onset of symptoms and
b) jaundice or elevated serum aminotransferase levels
Laboratory
Criteria
IgM antibody to hepatitis B core antigen (anti-HBc) positive
OR
hepatitis B surface antigen (HBsAg) positive AND
IgM antibody to hepatitis A negative
doi:10.1371/journal.pone.0002626.t001
Acute Hepatitis B
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and at least one specific hepatitis B test within a 14 day period
yielded 272 cases of possible acute hepatitis B, including all 11
patients with positive IgM to core antigen. Exclusion of patients
with an ICD9 code for chronic hepatitis B or prior positive
laboratory tests for hepatitis B reduced the number of cases to 195.
Full text charts could not be located for 13 patients. Charts on the
remaining 182 patients were reviewed by an infectious disease
physician. Of these, 117 fulfilled criteria for acute hepatitis B and
54 for chronic hepatitis B. A confident diagnosis could not be
rendered in the remaining 11 cases. These were patients who
lacked clear documentation of their presenting symptoms, who
presented acutely with atypical symptoms (e.g. isolated epigastric
burning responsive to proton pump inhibitors), or had potential
alternative explanations for acute hepatitis (e.g. recent initiation of
hepatotoxic medications).
The accuracy of each candidate algorithm is presented in
Table 2. Simple presence of an ICD9 for acute hepatitis B without
regard to any other criteria had a positive predictive value of 0%
(0/50 cases, 95% confidence interval 0–6%). By contrast, CDC
criteria (elevated transaminases and a positive hepatitis B specific
test–algorithm B) yielded a positive predictive value of 47.2%
(117/248, 95% confidence interval 41–53%). Exclusion of patients
with prior hepatitis B positive tests or ICD9 codes for chronic
hepatitis B (algorithm C) raised the positive predictive value to
68.4% (117/171, 95% confidence interval 61–75%). The addition
of a requirement for ALT.1000 (algorithm D) raised the positive
predictive value to 96.5% (111/115, 95% confidence interval 93–
100%) with sensitivity 95% (111/117, 95% confidence interval
91–99%) and specificity 93% (50/54, 95% confidence interval 86–
100%). Algorithm E substituted total bilirubin.1.5 rather than
ALT.1000. This yielded a positive predictive value of 97.4%
Table 2. Sensitivity and specificity of candidate algorithms to identify acute hepatitis B.
Algorithm Algorithm Components
Total
Patients
Positive Predictive
Value Sensitivity Specificity
A 1 only 1. ICD9 for acute hepatitis B (070.30) 2564 0/50 (0%, 95% CI,
0–6%)*
*** ***
B (1and 2) or 3 1. ALT or AST$56normal OR ICD9 for jaundice AND 272 117/248 (47.2%,
95% CI, 41–53%)**
*** ***
2. Anti-HBc reactive within a 14 day period OR HBsAg positive within a
14 day period OR hepatitis B viral DNA positive within a 14 day period
3. Current HBsAg positive with prior HBsAg negative within preceding
year
C (1and 2 and 3)
or 4
1. ALT or AST$56normal OR ICD9 for jaundice AND 195 117/171 (68.4%,
95% CI, 61–75%) **
*** ***
2. Anti-HBc reactive within a 14 day period OR HBsAg positive within a
14 day period OR hepatitis B viral DNA positive within a 14 day period
3. No ICD9 code for chronic hepatitis B (070.32) in medical record OR
prior positive HBsAg OR prior positive hepatitis B viral DNA
4. Current HBsAg positive with prior HBsAg negative within preceding
year
D (1 and 2 and 3
and 4) or 5
1. ALT or AST$56normal OR ICD9 for jaundice AND 115 111/115 (96.5%,
95% CI, 93–100%)
111/117
(94.9%, 95%
CI, 91–99%)
50/54 (92.6%,
95% CI, 86–
100%)
2. Anti-HBc reactive within a 14 day period OR HBsAg positive within a
14 day period OR hepatitis B viral DNA positive within a 14 day period
3. No ICD9 code for chronic hepatitis B (070.32) in medical record OR
prior positive HBsAg OR prior positive hepatitis B viral DNA
4. ALT.1000
5. Current HBsAg positive with prior HBsAg negative within preceding
year
E (1 and 2 and 3
and 4) or 5
1. ALT or AST$56normal OR ICD9 for jaundice AND 115 112/115 (97.4%,
95% CI, 94–100%)
112/113
(99.1%, 95%
CI, 97–100%)
45/48 (93.8%,
95% CI, 87–
100%)
2. Anti-HBc reactive within a 14 day period OR HBsAg positive within a
14 day period OR hepatitis B viral DNA positive within a 14 day period
3. No ICD9 code for chronic hepatitis B (070.32) in medical record OR
prior positive HBsAg OR prior positive hepatitis B viral DNA
4. Total bilirubin.1.5
5. Current HBsAg positive with prior HBsAg negative within preceding year
ABBREVIATIONS: ICD9–International Classification of Disease, Ninth Revision, Clinical Modification; ALT–alanine aminotransferase; AST–aspartate aminotransferase; HBc–
hepatitis B core antigen; HBsAg–hepatitis B surface antigen.
*random selection of 50 patients seen between 2006 and 2007.
**denominators lower than total number of patients due to missing data and exclusion of ambiguous cases.
***sensitivity and specificity not available for algorithms A–C since the reference standard for sensitivity and specificity calculation derived from chart review of patients
identified by algorithm C.
doi:10.1371/journal.pone.0002626.t002
Acute Hepatitis B
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(112/113, 95% confidence interval 97–100%) and specificity 94%
(45/48, 95% confidence interval 87–100%).
Algorithm E was subsequently applied to prospectively collected
electronic medical record data from over 600,000 patients seen in
Atrius Health between June 2006 and April 2008. During this
period, 2684 positive hepatitis B specific tests were obtained for
601 patients. Of these, 8 were flagged as acute hepatitis B by
algorithm E. Chart review confirmed all 8 to be true positive cases
(100% positive predictive value).
The incidence-density of acute hepatitis B in the validation set
was 0.70 cases/100,000 patients. For comparison sake, the annual
incidence density in derivation set in the years 2004, 2005, and
2006 was 0.77, 0.67, and 0.59 cases/100,000 patients respectively
(Figure 1).
State health department records of acute hepatitis B cases
diagnosed during the validation period were searched for patients
with acute hepatitis B independently reported by laboratories and
Atrius Health clinicians. Of the 8 cases found by the algorithm, 4
were already known to the state health department from
spontaneous reporting but only 1 of those 4 cases was labelled
as acute infection. The other 3 were recorded as hepatitis B
without comment on whether acute or chronic. There were no
Atrius Health patients with acute hepatitis B known to the state
health department that were missed by the algorithm.
Discussion
Algorithms applied to electronic medical record data can
accurately identify cases of acute hepatitis B. The best electronic
algorithm achieved a sensitivity of 99% and specificity of 94% for
acute hepatitis B. When applied to two years of prospective
electronic medical record data, the algorithm found 8 true cases
including 4 cases that clinicians and laboratories had failed to
report to the health department, and 3 cases reported to the health
department as hepatitis B alone without indication of whether
acute or chronic. There were no false positive cases and no known
cases missed.
The high accuracy of the final algorithm was achieved by
integrating multiple streams of data from the electronic medical
record including current biochemical tests, the results of prior
hepatitis B testing, and ICD9 coding. Of note, 2 acute biochemical
findings appear helpful to identify acute infections: peak
ALT.1000 and total bilirubin.1.5.
The single case of confirmed acute hepatitis B in our cohort
without a total bilirubin.1.5 may have been an artefact of timing of
lab measurements. This patient only had bilirubin measured at the
time of initial presentation. The patient’s transaminases continued to
rise in subsequent days but his bilirubin was not measured again.
Sincebilirubinelevation isknown tolag slightlybehind transaminase
elevation, the patient might have met algorithm criteria for acute
infection if bilirubin been measured again on a subsequent visit.
Neither ALT.1000 nor total bilirubin.1.5 criteria are 100%
specific. Four patients with chronic hepatitis B presented with
ALT .1000 and 3 patients with chronic infection had total
bilirubin .1.5. One patient with chronic hepatitis B who
presented with an ALT of 1086 was diagnosed with cholecystitis.
There were no clear precipitants identified for the unusually high
ALT values seen in the other three patients with underlying
chronic hepatitis B. Sources of hyperbilirubinemia in chronic
hepatitis B patients included cholecystitis and end-stage cirrhosis.
These false positives are consistent with previous studies in which
patients with flares of chronic hepatitis B occasionally present with
very high transaminases and bilirubin. Davis and Hoofnagle, for
example,prospectivelyfollowed150patientswithchronichepatitisB
and found that two developed clinical jaundice from flares of their
hepatitis B.[15] Our algorithm is designed to minimize these sources
of false positives by excluding patients with prior positive hepatitis B
tests or an ICD9 code for chronic infection in their electronic
medical records.Theseexclusion criteria combined with therarity of
cholestasis insevereflares ofchronichepatitis B likelyaccountfor the
Figure 1. Annual incidence-density of acute hepatitis B in the derivation dataset (Harvard Vanguard Medical Associates, January
1994–May 2006) and in the validation dataset (Atrius Health, June 2006–April 2008).
doi:10.1371/journal.pone.0002626.g001
Acute Hepatitis B
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flares of chronic infection.
It is unlikely that the physician chart reviewer’s subjective
judgment of acute versus chronic disease influenced the relative
performance of the algorithms. Serial hepatitis B surface antigen
tests were available for 82% of patients; the patterns of change in
surface antigenemia over time confirmed the physician reviewer’s
clinical impression in all cases in which serial tests were available.
These confirmatory changes in surface antigenemia decrease the
likelihood that acute cases of anicteric disease were misclassified as
chronic infections.
Previous studies suggest that some cases of acute hepatitis B are
clinically silent.[16,17] These patients were likely missed by this
analysis since by definition it was limited to patients who presented
for clinical evaluation. Our algorithms do incorporate a strategy
for seeking clinically silent acute cases of disease (serial change in
hepatitis B surface antigen from negative to positive in a patient
without known prior infection) but this strategy is still contingent
upon patients with silent disease presenting for clinical care and
eliciting sufficient clinical suspicion to prompt serial surface
antigen testing. These are admittedly rare circumstances.
The poor positive predictive value of ICD9 code 070.30 for
acute hepatitis B (0%, 95% confidence interval 0–6%) is likely an
artefact of the text description given to this code in our practice’s
electronic medical record. It is labelled as ‘‘hepatitis B’’ alone
rather than ‘‘acute hepatitis B’’ and hence is commonly used by
clinicians for asymptomatic patients found to have evidence of
remote exposure to hepatitis B or ongoing chronic disease despite
the presence of a specific alternative code for chronic disease. The
poor performance of ICD9 codes for hepatitis surveillance is
consistent with previous work and underscores the poor accuracy
of disease surveillance using ICD9 codes alone.[10]
Similarly, the small number of cases of acute disease detected by
screening for positive IgM to hepatitis B core antigen reveals the
limitation of population surveillance for acute disease using this
test alone. The poor sensitivity of IgM to core antigen for
population-level surveillance is a consequence of the test rarely
being ordered. In our series of 195 patients presenting with
elevated transaminases and a positive hepatitis B specific test, only
20 patients went on to have IgM to core antigen assayed.
Analysis of the distribution of other positive hepatitis B specific
tests relative to the number of patients ultimately found to have
acute hepatitis B is a further window into the benefit of
comprehensive electronic medical record data for notifiable
disease surveillance relative to conventional laboratory-based
reporting systems. Laboratory-based reporting systems would
have generated 2648 reports of patients with hepatitis B without
flagging the eight acute cases from the many more chronic cases
(Table 3). By contrast, an algorithm leveraging diverse streams of
electronic medical record data reliably identified the handful of
acute cases within this large pool of positive tests.
A potential limitation of this work is the small size of the
validation dataset relative to the derivation set. Nonetheless,
disparate lines of evidence suggest that the validation is accurate.
In and of itself, the validation set is large, covering 1.2 million
patient-years. All cases found in the validation set were true
positives, mirroring the high positive predictive value of the
algorithm in the derivation set. The incidence-density of acute
hepatitis B in the validation set closely matched the incidence-
density in the final years of the derivation set. Finally, comparison
of case capture in the validation set with the state health
department’s database of independently reported cases of acute
hepatitis B failed to reveal any cases missed by the algorithm.
This work shows that it is possible to accurately identify acute
hepatitis B from electronic medical record data. The final
algorithm described in this work is now being used for live,
prospective surveillance within Atrius Health–the last 3 of the 8
acute cases described in this dataset were prospectively detected.
The performance of the acute hepatitis B algorithm suggests that it
is feasible to overcome some of the limitations of clinician-initiated
and electronic laboratory based reporting of notifiable diseases by
identifying complex diseases from electronic medical records.
Integration of algorithms such as the one developed here into live
disease detection and reporting systems that analyze real-time
electronic health data promises to improve the quality, complete-
ness, and timeliness of public health surveillance.
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